Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FN-1501 in Advanced Solid Tumors or Relapsed/Refractory AML
NCT03690154Phase 1Terminated
- Sponsor
- Fosun Pharma
- Start
- Jul 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of FN-1501 in solid tumor (advanced stage) and acute myeloid leukemia (AML), sponsored by Fosun Pharma. Primary endpoints: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) and Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D). Started Jul 2018; status: terminated.
02
Drugs
FN-1501
03
Conditions
solid tumor (advanced stage)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03690154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690154.